Join to View Full Profile
20 Duke Medicine CirDurham, NC 27710
Dr. Hoimes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Christopher Hoimes, is a genitourinary and Phase I oncologist on faculty at Duke University. He completed fellowships in hematology and medical oncology and genitourinary oncology at Yale University, and his residency in internal medicine at Penn State Hershey Medical Center. He has previously been on faculty at Penn State University, Yale, Case Western University.
Education & Training
Yale School of MedicinePost-Doctoral Fellowship, 2008 - 2012
Yale-New Haven HospitalFellowship, Genitourinary Oncology, 2009 - 2010- Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Penn State Milton S Hershey Medical CenterChief Residency, Internal Medicine, 2005 - 2006- Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 2002 - 2005
NYIT College Of Osteopathic MedicineClass of 2001
Certifications & Licensure
OH State License 2013 - 2026
NC State License 2020 - 2025
CT State License 2009 - 2013
PA State License 2002 - 2012
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
- Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects Start of enrollment: 2015 May 27
Publications & Presentations
PubMed
- 4 citationsPembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.Julie N Graff, Christopher J Hoimes, Winald R Gerritsen, Ulka N Vaishampayan, Tony Elliott
Prostate Cancer and Prostatic Diseases. 2025-06-01 - Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting.Emma L Myers, Jessica Liu, Sabrina M Shearer, Sarah A Myers, Michelle Schneider
JAAD Case Reports. 2025-04-01 - 10 citationsAssociation of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.John P Sfakianos, Arnab Basu, George Laliotis, Shivaram Cumarasamy, Jordan M Rich
European Urology Oncology. 2025-04-01
Books/Book Chapters
Press Mentions
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder CancerSeptember 28th, 2019
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
